Does Chemotherapy Cause Viral Relapse in Cancer Patients With Hepatitis C Infection Successfully Treated With Antivirals?

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 6, 2014, Pages

  Mahale, Parag ^a,b   Okhuysen, Pablo C ^a   Torres, Harrys A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Chemotherapy; Hepatitis C virus; Interferon; Ribavirin; SVR

Indexed keywords

BENDAMUSTINE; BEVACIZUMAB; BOCEPREVIR; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MELPHALAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; RIBAVIRIN; RITUXIMAB; SORAFENIB; TELAPREVIR; TEMOZOLOMIDE; THALIDOMIDE; VINCRISTINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RADIOFREQUENCY ABLATION; RECTUM CANCER; RELAPSE; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; VIRUS REACTIVATION; COMPLICATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; INCIDENCE; ISOLATION AND PURIFICATION; LIVER NEOPLASMS; MIDDLE AGED; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84901189832     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.10.034     Document Type: Article

References (15)

1. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
2. Fujiwara K., Allison R.D., Wang R.Y., et al. Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 2013, 57:483-491.
3. Halfon P., Martinot-Peignoux M., Cacoub P. The myth of occult hepatitis C infection. Hepatology 2009, 50:1675.
4. Halfon P., Bourlière M., Ouzan D., et al. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. JClin Microbiol 2008, 46:2106-2108.
5. Seeff L.B. Sustained virologic response: is this equivalent to cure of chronic hepatitis C?. Hepatology 2013, 57:438-440.
6. Castillo I., Pardo M., Bartolomé J., et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. JInfect Dis 2003, 189:7-14.
7. Carreño V., Pardo M., López-Alcorocho J.M., et al. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. JInfect Dis 2006, 194:53-60.
8. Feld J.J., Liang T.J. HCV persistence: cure is still a four letter word. Hepatology 2005, 41:23-25.
9. MacParland S.A., Pham T.N., Guy C.S., et al. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity invitro. Hepatology 2009, 49:1431-1441.
10. Mahale P., Kontoyiannis D.P., Chemaly R.F., et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. JHepatol 2012, 57:1177-1185.
11. Swain M.G., Lai M.Y., Shiffman M.L., et al. Asustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010, 139:1593-1601.
12. Welker M.W., Zeuzem S. Occult hepatitis C: how convincing are the current data?. Hepatology 2009, 49:665-675.
13. Lee W.M., Polson J.E., Carney D.S., et al. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. JInfect Dis 2005, 192:1088-1092.
14. Lin A., Thadareddy A., Goldstein M.J., et al. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. JMed Virol 2008, 80:1720-1722.
15. Colson P., Bregigeon S., Tourres C., et al. Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient. JClin Virol 2013, 58:309-314.